Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
R.A.Bekker1, Yu.V.Bykov2 1David Ben-Gurion University in the Negev. 8410501, Israel, Beer-Sheva; 2Stavropol State Medical University of the Ministry of Health of the Russian Federation. 355017, Russian Federation, Stavropol, ul. Mira, d. 310
Список исп. литературыСкрыть список 1. Александровский Ю.А. Бензодиазепины из Польши – надежные и эффективные препараты. Психиатрия и психофармакотерапия. 2014; 16 (5): 21–4. / Aleksandrovsky Yu.A. Benzodiazepines from Poland – reliable and effective drugs. Psychiatry and Psychopharmacotherapy. 2014; 16 (5): 21–4. [in Russian] 2. Арутюнян К.А., Шевченко П.П. Варианты лечения рассеянного склероза в случаях обострения. Междунар. студенческий науч. вестн. 2016; 4 (1): 51–3. / Arutiunian K.A., Shevchenko P.P. Varianty lecheniia rasseiannogo skleroza v sluchaiakh obostreniia. Mezhdunar. studencheskii nauch. vestn. 2016; 4 (1): 51–3. [in Russian] 3. Беккер Р.А., Быков Ю.В. Акатизия: клинический анализ патологии с рекомендациями и обзором литературы. http://www.con-med.ru/partner_article/ / Bekker R.A., Bykov Yu.V. Akathisia: a clinical overview with literature review and recommendations. http://www.con-med.ru/partner_article/ [in Russian] 4. Беккер Р.А., Быков Ю.В. Когнитивные нарушения при депрессиях: клиническое значение и современные возможности терапии. Психиатрия и психофармакотерапия. 2015; 17 (4): 40–5. / Bekker R.A., Bykov Yu.V. Cognitive impairment in depression: clinical significance and current treatment options. Psychiatry and Psychopharmacotherapy. 2015; 17 (4): 40–5. [in Russian] 5. Беккер Р.А., Быков Ю.В. Лоразепам: обзор применения. Психиатрия и психофармакотерапия. 2016; 18 (4): 19–27. / Bekker R.A., Bykov Yu.V. Lorazepam’s clinical utility: a literature review. Psychiatry and Psychopharmacotherapy. 2016; 18 (4): 19–27. [in Russian] 6. Быков Ю.В., Беккер Р.А., Резников М.К. Депрессии и резистентность (практическое руководство). М.: ИНФРА-М, 2013. / Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost' (prakticheskoe rukovodstvo). M.: INFRA-M, 2013. [in Russian] 7. Воробьева О.В., Голубев В.Л. Клоназепам в терапии эпилептических и неэпилептических пароксизмальных состояний. Мед. алфавит. 2015; 2 (19): 18–22. / Vorob'eva O.V., Golubev V.L. Klonazepam v terapii epilepticheskikh i neepilepticheskikh paroksizmal'nykh sostoianii. Med. alfavit. 2015; 2 (19): 18–22. [in Russian] 8. Воробьева О.В. Бензодиазепины: от скептицизма к рациональной (взвешенной) позиции. Психиатрия и психофармакотерапия. 2015; 17 (4): 19–24. / Vorobyova O.V. Benzodiazepines: from skepticism to a rational (weighted) positions. Psychiatry and Psychopharmacotherapy. [in Russian] 9. Давыдов А.Т., Тюкавин А.И., Антонов М.М. и др. Птаология боли, роль и место различных методов лечения болевого синдрома. Обзоры по клин. фармакологии и лекарственной терапии. 2013; 11 (1): 55–75. / Davydov A.T., Tiukavin A.I., Antonov M.M. i dr. Ptaologiia boli, rol' i mesto razlichnykh metodov lecheniia bolevogo sindroma. Obzory po klin. farmakologii i lekarstvennoi terapii. 2013; 11 (1): 55–75. [in Russian] 10. Давыдов А.Т., Тюкавин А.И., Резванцев М.В. и др. Фантомная боль, роль и место различных методов лечения фантомно-болевого синдрома. Обзоры по клин. фармакологии и лекарственной терапии. 2014; 12 (1): 35–58. / Davydov A.T., Tiukavin A.I., Rezvantsev M.V. i dr. Fantomnaia bol', rol' i mesto razlichnykh metodov lecheniia fantomno-bolevogo sindroma. Obzory po klin. farmakologii i lekarstvennoi terapii. 2014; 12 (1): 35–58. [in Russian] 11. Данилов А.Б. Диагностика и лечение фибромиалгии. Эффективная фармакотерапия. 2010; 18: 52–8. / Danilov A.B. Diagnostika i lechenie fibromialgii. Effektivnaia farmakoterapiia. 2010; 18: 52–8. [in Russian] 12. Евтушенко С.К., Омельяненко А.А. Идиопатические генерализованные эпилепсии. Новости медицины и фармации. 2011; 5 (388): 52–7. / Evtushenko S.K., Omel'ianenko A.A. Idiopaticheskie generalizovannye epilepsii. Novosti meditsiny i farmatsii. 2011; 5 (388): 52–7. [in Russian] 13. Замерград М.В. Современные методы медикаментозного лечения вестибулярных нарушений. Неврология, нейропсихиатрия, психосоматика. 2012; 3: 92–5. / Zamergrad M.V. Sovremennye metody medikamentoznogo lecheniia vestibuliarnykh narushenii. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2012; 3: 92–5. [in Russian] 14. Иванец Н.Н., Кинкулькина М.А., Авдеева Т.И., Сысоева В.П. Психофармаккотерапия тревожных расстройств у больных пожилого возраста: эффективность, переносимость и современная роль лечения анксиолитиками. Соц. и клин. психиатрия. 2014; 24 (2): 60–71. / Ivanets N.N., Kinkul'kina M.A., Avdeeva T.I., Sysoeva V.P. Psikhofarmakkoterapiia trevozhnykh rasstroistv u bol'nykh pozhilogo vozrasta: effektivnost', perenosimost' i sovremennaia rol' lecheniia anksiolitikami. Sots. i klin. psikhiatriia. 2014; 24 (2): 60–71. [in Russian] 15. Кадыков А.С., Шахпаронова Н.В. Больной после инсульта на приеме у невролога. Мед. совет. 2013; 6: 76–83. / Kadykov A.S., Shakhparonova N.V. Bol'noi posle insul'ta na prieme u nevrologa. Med. sovet. 2013; 6: 76–83. [in Russian] 16. Катушкина Э.А., Зиновьева О.Е. Патогенез и лечение боли при диабетической невропатии. Мед. совет. 2014; 7: 43–7. / Katushkina E.A., Zinov'eva O.E. Patogenez i lechenie boli pri diabeticheskoi nevropatii. Med. sovet. 2014; 7: 43–7. [in Russian] 17. Кожинова А.В., Левин О.С. Фармакотерапия больных, перенесших ишемический инсульт, в период реабилитации. Соврем. терапия в психиатрии и неврологии. 2015; 1: 4–11. / Kozhinova A.V., Levin O.S. Farmakoterapiia bol'nykh, perenesshikh ishemicheskii insul't, v period reabilitatsii. Sovrem. terapiia v psikhiatrii i nevrologii. 2015; 1: 4–11. [in Russian] 18. Ладыженский М.Я., Городничев А.В., Костюкова Е.Г. Бензодиазепиновые анксиолитики: востребованы ли они сегодня? Соврем. терапия психических расстройств. 2014; 2: 20–5. / Ladyzhenskii M.Ia., Gorodnichev A.V., Kostiukova E.G. Benzodiazepinovye anksiolitiki: vostrebovany li oni segodnia? Sovrem. terapiia psikhicheskikh rasstroistv. 2014; 2: 20–5. [in Russian] 19. Морозова О.Г. Синдром головокружения: механизмы развития, диагностика и терапевтическая стратегия. Новости медицины и фармации. 2012; 4 (428): 57–70. / Morozova O.G. Sindrom golovokruzheniia: mekhanizmy razvitiia, diagnostika i terapevticheskaia strategiia. Novosti meditsiny i farmatsii. 2012; 4 (428): 57–70. [in Russian] 20. Нуллер Ю.Л., Михайленко И.Н. Аффективные психозы. Л.: Медицина, 1988. / Nuller Iu.L., Mikhailenko I.N. Affektivnye psikhozy. L.: Meditsina, 1988. [in Russian] 21. Ретюнский К.Ю., Детков Д.В., Забродин О.В. Влияние патогенетической психофармакотерапии на длительность ремиссий при алкоголизме в подростковом возрасте. Урал. мед. журн. 2011; 11: 61–7. / Retiunskii K.Iu., Detkov D.V., Zabrodin O.V. Vliianie patogeneticheskoi psikhofarmakoterapii na dlitel'nost' remissii pri alkogolizme v podrostkovom vozraste. Ural. med. zhurn. 2011; 11: 61–7. [in Russian] 22. Ростовщиков В.В., Иванчук Э.Г. Современные аспекты диагностики и лечения панических расстройств. Лекарственный вестн. 2013; 7 (1): 43–8. / Rostovshchikov V.V., Ivanchuk E.G. Sovremennye aspekty diagnostiki i lecheniia panicheskikh rasstroistv. Lekarstvennyi vestn. 2013; 7 (1): 43–8. [in Russian] 23. Селиверстов Ю.А., Клюшников С.А. Современные подходы к медикаментозной коррекции хореи при болезни Гентингтона. Нервные болезни. 2014; 3: 24–8. / Seliverstov Iu.A., Kliushnikov S.A. Sovremennye podkhody k medikamentoznoi korrektsii khorei pri bolezni Gentingtona. Nervnye bolezni. 2014; 3: 24–8. [in Russian] 24. Хабиров Ф.А., Хабирова Ю.Ф. Боли в шее и спине (диагностика, клиника и лечение). Практ. медицина. 2012; 2 (57): 23–8. / Khabirov F.A., Khabirova Iu.F. Boli v shee i spine (diagnostika, klinika i lechenie). Prakt. meditsina. 2012; 2 (57): 23–8. [in Russian] 25. Шавловская О.А. Комплексная терапия писчего спазма. Мед. алфавит. 2016; 2 (14): 53–7. / Shavlovskaia O.A. Kompleksnaia terapiia pischego spazma. Med. alfavit. 2016; 2 (14): 53–7. [in Russian] 26. Шатрова В.П., Аганесов А.Г. Лечение корешкового синдрома у больных с вертеброгенной патологией. Московский хирургич. журн. 2011; 4: 27–31. / Shatrova V.P., Aganesov A.G. Lechenie koreshkovogo sindroma u bol'nykh s vertebrogennoi patologiei. Moskovskii khirurgich. zhurn. 2011; 4: 27–31. [in Russian] 27. Abramowitz JS, McKay D, Taylor S. Obsessive-Compulsive Disorder: Subtypes and Spectrum Conditions. 1st Ed. Elsevier Science, 2011. 28. Ahlawat SK. Severe hyponatremia in a chronic schizophrenic patient. J Assoc Physicians India 1999; 47 (7): 724–6. 29. Alessi-Severini S, Bolton JM, Enns MW et al. Sustained Use of Benzodiazepines and Escalation to High Doses in a Canadian Population. Psychiatr Serv 2016; 67 (9): 1012–8. 30. Amann B, Grunze H. The evolution of antiepileptic drugs for mood stabilization and their main mechanisms of action. Expert Rev Neurother 2003; 3 (1): 107–18. 31. Arikawa A, Mito H, Motoyama M et al. A Case with Multiple Comorbidities of Obsessive-Compulsive and Related Disorders. [Article in Japanese]. Seishin Shinkeigaku Zasshi 2015; 117 (11): 893–901. 32. Basu B, Gangopadhyay T, Dutta N et al. A case of akathisia induced by escitalopram: case report & review of literature. Curr Drug Saf 2014; 9 (1): 56–9. 33. Beiske GA, Holmøy T, Beiske AG et al. Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis. Mult Scler Int 2015; 2015: 317859. 34. Bisdorff AR. Management of vestibular migraine. Ther Adv Neurol Disord 2011; 4 (3): 183–91. 35. Brondino N, Fusar-Poli L, Panisi C et al. Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies. J Autism Dev Disord 2016; 46 (3): 825–39. 36. Carminati GG, Gerber F, Darbellay B et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 2016; 65: 85–95. 37. Castle D, Bosanac P, Rossell S. Treating OCD: what to do when first-line therapies fail. Australas Psychiatry 2015; 23 (4): 350–3. 38. Chen JH, Huang Y, Liu XQ et al. Prevalence of REM sleep behavior disorder in patients with brainstem lesions. [Article in Chinese]. Zhonghua Yi Xue Za Zhi 2013; 93 (37): 2942–5. 39. Coffey B. Clinical case presentation: therapeutic challenges in adolescent-onset bipolar disorder. J Child Adolesc Psychopharmacol 2003; 13 (4): 425–30. 40. Cooper SJ, Gilbert DB. Clonazepam-induced hyperphagia in nondeprived rats: tests of pharmacological specificity with Ro5-4864, Ro5-3663, Ro15-1788 and CGS 9896. Pharmacol Biochem Behav 1985; 22 (5): 753–60. 41. Cooper SJ, Kirkham TC. Adrenalectomy and the anorectic effects of benzodiazepine inverse agonists and opiate antagonists in rats fed a palatable diet. Physiol Behav 1987; 40 (4): 479–82. 42. Cooper SJ. The anorectic effect of FG 7142, a partial inverse agonist at benzodiazepine recognition sites, is reversed by CGS 8216 and clonazepam but not food deprivation. Brain Res 1985; 346 (1): 190–4. 43. Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry 2004; 16 (3): 127–32. 44. Dokkedal V, Scorza FA, Galduroz JC et al. Epilepsy comorbidities: Is clonazepam a friend or a foe? Epilepsy Behav 2016; 62: 309–10. 45. Dunlop BW, Scheinberg K, Dunlop AL. Ten ways to improve the treatment of depression and anxiety in adults. Ment Health Fam Med 2013; 10 (3): 175–81. 46. Emre M, Ford PJ, Bilgiç B et al. Cognitive impairment and dementia in Parkinson's disease: practical issues and management. Mov Disord 2014; 29 (5): 663–72. 47. Fernández Hurst N, Chanaday NL, Roth GA. GABAergic Agonists Modulate the Glutamate Release from Frontal Cortex Synaptosomes of Rats with Experimental Autoimmune Encephalomyelitis. Inflamm Allergy Drug Targets 2015; 14 (2): 105–10. 48. Ganança MM, Caovilla HH, Ganança FF et al. Clonazepam in the pharmacological treatment of vertigo and tinnitus. Int Tinnitus J 2002; 8 (1): 50–3. 49. Geddes JR, Briess D. Bipolar disorder. BMJ Clin Evid 2007; 2007. pii: 1014. 50. Halayem S, Othman S, Ben Youssef H et al. The Usefulness of Clonazepam as an Augmentative Treatment in a Case of Severe Childhood Onset Obsessive-Compulsive Disorder. [Article in Turkish]. Turk Psikiyatri Derg 2015; 26 (4): 291–4. 51. Han S, Tai C, Westenbroek RE et al. Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 2012; 489 (7416): 385–90. 52. Hassan A, van Gerpen JA. Orthostatic Tremor and Orthostatic Myoclonus: Weight-bearing Hyperkinetic Disorders: A Systematic Review, New Insights, and Unresolved Questions. Tremor Other Hyperkinet Mov (N Y) 2016; 6: 417. 53. Healy D. The Creation of Psychopharmacology. 1st Ed. Harvard University Press, 2004. 54. Hoek HW, Treasure J, Katzman MA. Neurobiology in the Treatment of Eating Disorders (Clinical & Neurobiological Advances in Psychiatry). 1st Ed. Wiley, 2007. 55. Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 2003; 4 (1): 30–4. 56. Howell MJ, Schenck CH. Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Disease. JAMA Neurol 2015; 72 (6): 707–12. 57. Jacobsen JH, Rosenberg RS, Huttenlocher PR et al. Familial nocturnal cramping. Sleep 1986; 9 (1): 54–60. 58. Jankovic J. Therapeutic Developments for Tics and Myoclonus. Mov Disord 2015; 30 (11): 1566–73. 59. Jiménez-Jiménez FJ, García-Ruiz PJ. Pharmacological options for the treatment of Tourette's disorder. Drugs 2001; 61 (15): 2207–20. 60. Keski-Rahkonen A, Mustelin L. Epidemiology of eating disorders in Europe: prevalence, incidence, comorbidity, course, consequences, and risk factors. Curr Opin Psychiatry 2016; 29 (6): 340–5. 61. Knijnik DZ, Blanco C, Salum GA et al. A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry 2008; 23 (8): 567–74. 62. Ko SB, Ahn TB, Kim JM et al. A case of adult onset tic disorder following carbon monoxide intoxication. Can J Neurol Sci 2004; 31 (2): 268–70. 63. Koga M, Nakadozono M, Nukariya K et al. Clonazepam for chemotherapy-induced nausea and vomiting (CINV). Anticancer Res 2008; 28 (4C): 2433–6. 64. Kossoff EH, Singer HS. Tourette syndrome: clinical characteristics and current management strategies. Paediatr Drugs 2001; 3 (5): 355–63. 65. Litvinenko IV, Krasakov IV, Tikhomirova OV. Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova 2012;112 (12): 26–30. 66. Maizels M. Clonazepam for refractory headache: three cases illustrative of benefit and risk. Headache 2010; 50 (4): 650–6. 67. Maremmani AG, Rovai L, Rugani F et al. Clonazepam as agonist substitution treatment for benzodiazepine dependence: a case report. Case Rep Psychiatry 2013; 2013: 367594. 68. Meador W, Salter AR, Rinker JR 2nd. Symptomatic Management of Multiple Sclerosis-Associated Tremor Among Participants in the NARCOMS Registry. Int J MS Care 2016; 18 (3): 147–53. 69. Menard ML, Yagoubi F, Drici M et al. Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms. [Article in French]. Encephale 2013; 39 (Suppl. 1): S29–35. 70. Mendonça Júnior FJ, Scotti L et al. Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders. Mini Rev Med Chem 2015; 15 (8): 630–47. 71. Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr 2016; 21 (S1): 13–24. 72. Mowla A, Ahmadzadeh L, Razeghian Jahromi L et al. Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial. Clin Drug Investig 2015; 35 (8): 513–7. 73. Ochoa JG, Kilgo WA. The Role of Benzodiazepines in the Treatment of Epilepsy. Curr Treat Options Neurol 2016; 18 (4): 18. 74. Perna G, Alciati A, Riva A et al. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep 2016; 18 (3): 23. 75. Pollack MH, Van Ameringen M, Simon NM et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 2014; 171 (1): 44–53. 76. Poucher M, Cherrier C, Poucher AC et al. Changing general medical practices in the management of neuropathic pain. [Article in French]. Sante Publique 2016; 28 (4): 505–16. 77. Rahimi A, Ahmadpanah M, Shamsaei F et al. Effect of adjuvant sleep hygiene psychoeducation and lorazepam on depression and sleep quality in patients with major depressive disorders: results from a randomized three-arm intervention. Neuropsychiatr Dis Treat 2016; 12: 1507–15. 78. Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2012; 1: CD008922. 79. Rinaldi F, Galbiati A, Marelli S et al. Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED). Curr Treat Options Neurol 2016; 18 (2): 7. 80. Sachdev P. Citalopram-Clonazepam combination for primary depersonalization disorder: a case report. Aust N Z J Psychiatry 2002; 36 (3): 424–5. 81. Savitz AJ, Kahn TA, McGovern KE et al. Carbon dioxide induction of panic anxiety in schizophrenia with auditory hallucinations. Psychiatry Res 2011; 189 (1): 38–42. 82. Schaller JL, Behar D. Treating comorbid ADHD, major depression, and panic. J Neuropsychiatry Clin Neurosci 1999; 11 (4): 516. 83. Schenck CH, Hurwitz TD, Bundlie SR et al. Sleep-related eating disorders: polysomnographic correlates of a heterogeneous syndrome distinct from daytime eating disorders. Sleep 1991; 14 (5): 419–31. 84. Schenck CH, Hurwitz TD, O'Connor KA. Additional categories of sleep-related eating disorders and the current status of treatment. Sleep 1993; 16 (5): 457–66. 85. Sears J, Patel NC. Development of tics in a thirteen-year-old male following atomoxetine use. CNS Spectr 2008; 13 (4): 301–3. 86. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65 (2): 244–8. 87. Seeman MV. Sleepwalking, a possible side effect of antipsychotic medication. Psychiatr Q 2011; 82 (1): 59–67. 88. Sierra M. Depersonalization disorder: pharmacological approaches. Expert Rev Neurother 2008; 8 (1): 19–26. 89. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. (Cambridge Medicine). 1st Ed. Cambridge University Press, 2012. 90. Silberman EK. The role of benzodiazepines in treating social anxiety disorder. Am J Psychiatry 2014; 171 (7): 795. 91. Simeon D, Abugel J. Feeling Unreal: Depersonalization Disorder and the Loss of the Self. 1st Ed. Oxford University Press, 2008. 92. Steketee G. The Oxford Handbook of Obsessive Compulsive and Spectrum Disorders (Oxford Library of Psychology). 1st Ed. Oxford University Press, 2011. 93. Stinton C, McKeith I, Taylor JP et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry 2015; 172 (8): 731–42. 94. Sugimoto T, Murata T, Omori M et al. Clonazepam augmentation therapy in a male at early adolescence with rapid cycling bipolar disorder. Gen Hosp Psychiatry 2003; 25 (1): 57–9. 95. Tachibana N, Sugita Y, Teshima Y et al. A case of anorexia nervosa associated with epileptic seizures showing favorable responses to sodium valproate and clonazepam. Jpn J Psychiatry Neurol 1989; 43 (1): 77–84. 96. Val AC, Souza A, Nicolato R et al. Catatonic syndrome associated with mixed bipolar disorder: a case report and therapeutic considerations. [Article in Portuguese]. Rev Bras Psiquiatr 2008; 30 (4): 399–400. 97. Veenstra-VanderWeele J, Cook EH, King BH et al. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology 2016. 98. Vidailhet M, Roze E, Maugest L et al. Lessons I have learned from my patients: everyday life with primary orthostatic tremor. J Clin Mov Disord 2017; 4: 1. 99. Wayhs CA, Mescka CP, Guerreiro G et al. Diabetic encephalopathy-related depression: experimental evidence that insulin and clonazepam restore antioxidant status in rat brain. Cell Biochem Funct 2014; 32 (8): 711–9. 100. Wiffen P, Collins S, McQuay H et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005; 3: CD001133. 101. Winkler D, Willeit M, Wolf R et al. Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. Eur Neuropsychopharmacol 2003; 13 (2): 129–34. 102. Zesiewicz TA, Kuo SH. Essential tremor. BMJ Clin Evid. 2015; 2015. pii: 1206.